Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs Philip Morris International Inc. — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B), while Philip Morris International Inc. trades at $206.58 (market cap $310.62B). The key difference: Philip Morris International Inc. is far larger — about 74.3× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Philip Morris International Inc. pays a 3.21% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Philip Morris International Inc. for 85 Days on average.
| INDV | PM | |
|---|---|---|
Market Cap | $4.18B | $310.62B |
Volume | 1,819,746 | 4,145,126 |
Sector | Health | Consumer Staples |
52-Week High | $41.83 | $205.58 |
52-Week Low | $24.09 | $144.33 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $4.47B | $353.73B |
Dividend Yield | — | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $202.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $212.17. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.20, and maintains robust profitability with a net income margin of 25.56%. Recent news highlights growth in smoke-free products like IQOS and ZYN, now over 40% of revenue, and a raised 2026 EPS forecast due to favorable currency impacts.
The stock offers a compelling growth story driven by smoke-free product expansion and dividend reliability, but faces risks from regulatory pressures and high valuation multiples. With 68% of analysts rating it a Buy, upside exists toward the $225 high target, though investors should monitor debt levels and industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
